Table 3.
Top 20 reported adverse events among patients prescribed arthemeter–lumefantrine during follow-up contact by phone and home visit
| Adverse eventsa | Phone N = 157 n, % (95 % CI) |
Home N = 85 n, % (95 % CI) |
Total N = 242 n, % (95 % CI) |
|---|---|---|---|
| Drowsiness | 27, 17.2 (11.6–24.0) | 30, 35.3 (25.2–46.4) | 57, 23.6 (18.4–29.4) |
| Dizziness | 16, 10.2 (6.0–16.0) | 8, 9.4 (4.2–17.7) | 24, 9.9 (6.5–14.4) |
| General weakness | 14, 8.9 (5.0–14.5) | 3, 3.5 (1.01–0.10) | 17, 7.0 (4.1–11.0) |
| Vomiting | 12, 7.6 (4.0–13.0) | 8, 9.4 (4.2–17.7) | 20, 8.3 (5.1–12.5) |
| Headache | 9, 5.7 (3.0–10.6) | 3, 3.5 (0.7–10.0) | 12, 5.0 (3.0–9.0) |
| Body pains | 9, 5.7 (3.0–10.6) | 0, 0.0 (0.0–4.2) | 9, 3.7 (2.0–7.0) |
| Nausea | 7, 4.5 (2.0–9.0) | 2, 2.4 (0.3–8.2) | 9, 3.7 (2.0–7.0) |
| Fever | 7, 4.5 (2.0–9.0) | 1, 1.2 (0.0–6.4) | 8, 3.3 (1.4–6.4) |
| Stomach ache | 6, 3.8 (1.4–8.1) | 0, 0.0 (0.0–4.2) | 6, 2.5 (1.0–5.3) |
| Chills | 5, 3.2 (1.0–7.2) | 0, 0.0 (0.0–4.2) | 5, 2.1 (1.1–4.8) |
| Diarrhoea | 4, 2.5 (1.0–6.3) | 1, 1.2 (0.0–6.4) | 5, 2.1 (1.1–4.8,) |
| Sleeplessness | 4, 2.5 (1.0–6.3) | 1, 1.2 (0.0–6.4) | 5, 2.1 (1.1–4.8) |
| Cough | 3, 1.9 (0.4–5.4) | 5, 5.9 (2.0–13.2) | 8, 3.3 (1.4–6.4) |
| Body itchiness | 3, 1.9 (0.4–5.4) | 3, 3.5 (1.0–1.1) | 6, 2.5 (1.0–5.3) |
| Palpitation | 3, 1.9 (0.4–5.4) | 3, 3.5 (0.7–10.0) | 6, 2.5 (1.0–5.3) |
| Loss of appetite | 3, 1.9 (0.4–5.4) | 1, 1.2 (0.0–6.4) | 4, 1.7 (0.1–4.2) |
| Body itchiness | 3, 1.9 (0.4–5.4) | 3, 3.5 (07–10.0) | 3, 1.2 (0.3–4.0) |
| Cold | 3, 1.9 (0.4–5.4) | 0, 0.0 (0.0–4.2) | 3, 1.2 (0.3–4.0) |
| Chest pain | 2, 1.3 (0.1–5.0) | 0, 0.0 (0.0–4.2) | 2, 0.8 (0.1–3.0) |
| Loose stools | 2, 1.3 (0.1–5.0) | 0, 0.0 (0.0–4.2) | 2, 0.8 (0.1–3.0) |
aOne patient could report more than one adverse event